Pure Global AI
NCT06321731Not yet recruiting

Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

Observational Retrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in COPD Patients Initiating Trixeo Aerosphere (Budesonide/Glycopyrronium Bromide/Formoterol Fumarate) in Spain
AstraZenecaClinicalTrials.gov
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Timeline & enrollment
Phase
N/A
Start date
Jun 10, 2024
End date
Nov 30, 2024
Enrollment
500 participants
Primary outcome

Annualized rate of exacerbations after BGF initiation

Summary

The aim of the ORESTES study is to describe the characteristics of the COPD patients
 initiating Trixeo (BGF -budesonide/glycopyrronium/formoterol) in Spain and to assess their
 real-world outcomes up to 12 months afterwards.
 
 For that purpose,a descriptive, observational, multi-centre, longitudinal, retrospective
 cohort study involving ~20 Spanish centres and aiming to include between 500 and 700
 patients, has been designed.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06321731
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06321731 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.